Literature DB >> 2997653

Effects of tifluadom on food consumption compared with chlordiazepoxide and kappa agonists in the rat.

S J Cooper, W R Moores, A Jackson, D J Barber.   

Abstract

Tifluadom (0.625-10.0 mg kg-1) was administered to non-deprived male rats which had been accustomed to eating a highly palatable diet in a 30 min test period. This compound, an opioid benzodiazepine, produced a significant increase in consumption of food when administered by the subcutaneous route, but not after intraperitoneal injection. Both chlordiazepoxide (1.25-20.0 mg kg-1) and the selective kappa opiate receptor agonist U-50,488 (0.3125-2.5 mg kg-1) also produced significant hyperphagic effects in the same feeding situation. In contrast, the two kappa opiate receptor agonists, ethylketocyclazocine (0.1-3.0 mg kg-1) and bremazocine (0.078-1.25 mg kg-1) brought about a dose-related suppression of food intake. Hence, the effects of kappa opiate receptor agonists in the feeding situation described here were not uniform. Furthermore, tifluadom could be likened either to a benzodiazepine or to a selective kappa receptor agonist. The hyperphagia induced by tifluadom was antagonized by naloxone, suggesting that the effect was mediated by an action at opiate receptors. It was not antagonized however by Ro15-1788 (10.0 and 20.0 mg kg-1), a selective benzodiazepine receptor antagonist, ruling out possible mediation by benzodiazepine receptors. The benzodiazepine receptor antagonist, CGS 8216, exhibited intrinsic activity when administered alone, and significantly reduced food consumption in tifluadom-treated and control animals.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2997653     DOI: 10.1016/0028-3908(85)90039-5

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  6 in total

1.  Quipazine reduces food intake in the rat by activation of 5-HT2-receptors.

Authors:  G Hewson; G E Leighton; R G Hill; J Hughes
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

2.  The cholecystokinin receptor antagonist L364,718 increases food intake in the rat by attenuation of the action of endogenous cholecystokinin.

Authors:  G Hewson; G E Leighton; R G Hill; J Hughes
Journal:  Br J Pharmacol       Date:  1988-01       Impact factor: 8.739

3.  Reversal of the anorectic effect of (+)-fenfluramine in the rat by the selective cholecystokinin receptor antagonist MK-329.

Authors:  S J Cooper; C T Dourish; D J Barber
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

4.  Reduction of food intake by central administration of cholecystokinin octapeptide in the rat is dependent upon inhibition of brain peptidases.

Authors:  T Griesbacher; G E Leighton; R G Hill; J Hughes
Journal:  Br J Pharmacol       Date:  1989-01       Impact factor: 8.739

5.  Methocinnamox (MCAM) antagonizes the behavioral suppressant effects of morphine without impairing delayed matching-to-sample accuracy in rhesus monkeys.

Authors:  Vanessa Minervini; Alex Disney; Stephen M Husbands; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2020-08-09       Impact factor: 4.530

6.  Interactions between mu and kappa opioid agonists in the rat drug discrimination procedure.

Authors:  S S Negus; M J Picker; L A Dykstra
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.